In December 2019, a pneumonia due to a novel coronavirus (SARS-CoV-2) emerged in the city of Wuhan, in China. In a few weeks, the number of confirmed cases of SARS-CoV-2 infection has dramatically increased, with almost 150'000 cases and more than 6'000 reported deaths on March, 16th 2020. Little is known on the rate of human-to-human transmission of this new coronavirus SARS-CoV-2 in the community and within the hospital. Depending on the country, contact subjects considered to be at high or moderate risk of SARS-CoV-2 are, either isolated at home for a period of time defined by the health authorities or, on the contrary, continue their professional activity on the condition that they adopt measures to prevent transmission to those around them. In most European countries, healthcare workers adopt this second option. In all cases, it is most often recommended that contact persons monitor their state of health and communicate it to the persons dedicated to this action. Whether such subjects become spreaders of the virus is not known, nor is the proportion of viral spreader who will develop a symptomatic infection.
Procedures added by the research:
Phone calls for collection of reported symptoms. Nasopharyngeal swabs for determination of
the presence of SARS-CoV-2 detected by PCR.
Blood sampling for determination of the presence of SARS-CoV-2 IgM or IgG. Saliva or blood
sampling for whole exome sequencing of the subject.
Biological: 2019-nCoV PCR
Nasopharyngeal swabs
Inclusion Criteria:
1. High/moderate risk contact with a laboratory-confirmed SARS-CoV-2 case;
2. Within the 14 days following the last contact with a laboratory-confirmed SARS-CoV-2
case;
3. Obtaining informed consent.
Exclusion Criteria:
- Subject deprived of freedom
- Subject under a legal protective measure
Service de maladies infectieuses et tropicales Hôpital Jean Minjoz CHRU Besançon
Besançon, France
Service des Maladies infectieuses et tropicales, Pôle Spécialités médicales, CHU Pellegrin
Bordeaux, France
Service des maladies infectieuses Hôpital Gabriel Montpied CHU de Clermont Ferrand
Clermont-Ferrand, France
Centre d'investigation clinique 1432 Hôpital François Mitterrand CHU Bourgogne
Dijon, France
Centre d'investigation clinique 1406 CHU Grenoble
Grenoble, France
Centre d'Investigation Clinique 1403 -CHU Lille
Lille, France
Centre Investigation Clinique 1433 CHRU de NANCY
Nancy, France
Centre d'Investigation Clinique Hôpital Saint Louis
Paris, France
Centre d'investigation Clinique 1425, Hôpital Bichat Claude Bernard
Paris, France
Centre Investigation Clinique 1417 Hôpital Cochin Bâtiment Lavoisier
Paris, France
Centre d'investigation clinique 1414 Service de Pharmacologie clinique CHU Rennes Hôpital Pontchaillou
Rennes, France
Centre Hospitalier Félix Guyon Ile de la Réunion CHU nord
Saint Denis, France
Centre d'Investigation Clinique Ile de la Réunion CHU sud
Saint-Pierre, France
Département maladie infectieux CHU Saint Etienne
Saint-Étienne, France
Centre Investigation Clinique 1415 CHRU Tours - Hôpital Bretonneau
Tours, France
Service de Maladies infectieuses et tropicales Centre hospitalier
Cayenne, French Guiana
Xavier Duval, MD, Principal Investigator
Institut National de la Santé Et de la Recherche Médicale, France